The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1206
In Brief: Zegerid - Immediate-Release Omeprazole
Download PDF:   US English
Med Lett Drugs Ther. 2005 Apr 11;47(1206):29
Disclosures
Objective(s)
 Select a term to see related articles  Losec   Omeprazole   PPIs   Prilosec   Proton pump inhibitors   Zegerid 

The FDA has approved marketing of Zegerid powder for oral suspension (Santarus), an immediate-release formulation of the proton-pump inhibitor (PPI) omeprazole (Prilosec, and others). All other oral PPIs are delayed-release, enteric-coated formulations designed to prevent degradation of the drug by gastric acid. Each 20- or 40-mg packet of Zegerid contains 1680 mg of sodium bicarbonate, which protects the drug from gastric acid degradation. A dose of Zegerid contains 460 mg of sodium, which may be excessive for some patients. Zegerid is the first oral PPI to be approved by the FDA for reduction of risk of upper GI bleeding in critically ill patients. The drug may be useful for patients who are unable to swallow and have nasogastric (NG) tubes in place. Zegerid costs $70.00 for 14 days' treatment, compared to less than $10 for 14 tablets of Prilosec OTC.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
arrow to previous article
arrow to next article